News
SRZN
28.18
+0.75%
0.21
Weekly Report: what happened at SRZN last week (0928-1002)?
Weekly Report · 4d ago
Surrozen Initiated with Buy as IND Clearance, New Capital and External Wnt Validation Strengthen Clinical Momentum
TipRanks · 10/02 14:15
Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema
NASDAQ · 10/02 12:51
Surrozen advances diabetic macular edema candidate into clinic after IND clearance
Seeking Alpha · 10/02 12:45
Surrozen Wins FDA IND Clearance for SZN-8141 Program
TipRanks · 10/02 12:27
Surrozen announces FDA clearance of IND application for SZN-8141
TipRanks · 10/02 12:10
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Barchart · 10/02 07:00
Weekly Report: what happened at SRZN last week (0921-0925)?
Weekly Report · 09/28 09:31
Surrozen Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/25 12:04
Surrozen Price Target Raised to $54.00/Share From $44.00 by HC Wainwright & Co.
Dow Jones · 09/25 12:04
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Benzinga · 09/25 12:03
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
Benzinga · 09/25 11:52
Surrozen price target raised to $54 from $44 at H.C. Wainwright
TipRanks · 09/25 10:10
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/25 08:40
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 09/24 17:06
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Benzinga · 09/24 15:41
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Surrozen (SRZN) and aTyr Pharma (ATYR)
TipRanks · 09/24 15:21
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
Benzinga · 09/24 13:43
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 09/24 12:05
Two new option listings and eight option delistings on September 21st
TipRanks · 09/21 12:35
More
Webull provides a variety of real-time SRZN stock news. You can receive the latest news about Surrozen Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRZN
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.